{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T13:09:00Z","timestamp":1777727340897,"version":"3.51.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T00:00:00Z","timestamp":1631750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T00:00:00Z","timestamp":1631750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>We conducted a study to explore the relationship between pathological cytomorphologic features and the percentage of anaplastic lymphoma kinase (ALK)-positive cells to better predict pulmonary adenocarcinoma prognosis with crizotinib treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Patients and methods<\/jats:title>\n                <jats:p>We investigated 60 cases of patients with ALK-positive advanced or metastatic non-small cell lung cancer (NSCLC). Immunohistochemistry was performed to screen for ALK rearrangement. Fluorescence in situ hybridization (FISH) was used to detect the percentage of ALK-positive cells. The primary objectives of the study were the progression-free survival (PFS), the 3-year overall survival, and the 3-year overall survival (OS) rates. The secondary objectives of the study were the disease control rate (DCR) and the overall response rate (ORR).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We compared the pathological cytomorphologic features of 60 cases of ALK-positive pulmonary adenocarcinoma, of which 21 cases were ALK-positive with signet ring cell cytomorphologic characteristics. There were statistical differences in the ORR (<jats:italic>p<\/jats:italic> = 0.019), DCR (<jats:italic>p<\/jats:italic> = 0.032), and PFS (<jats:italic>p<\/jats:italic> = 0.047) between the signet ring cell group and group without signet ring cells. Of these, 37 cases were ALK-positive with EML4 (echinoderm microtubule associated protein like 4)-ALK high percentage of positivity group. These cases benefited more from crizotinib treatment in the ORR (<jats:italic>p<\/jats:italic> = 0.046) and achieved a longer PFS (<jats:italic>p<\/jats:italic> = 0.036) compared to those with EML4-ALK low percentage of positivity group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Signet ring cell cytomorphologic characteristics of pulmonary adenocarcinoma are associated with the percentage of ALK-positive cells. Signet ring cell cytomorphologic characteristics and the percentage of ALK-positive cells might predict the prognosis of pulmonary adenocarcinoma with crizotinib treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>The study was approved by the Institutional Review Board (Medical Ethics Committee of Yantai Yuhuangding Hospital). The registration number is NO.2016[193].<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12957-021-02386-0","type":"journal-article","created":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T16:04:34Z","timestamp":1631808274000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pathological cytomorphologic features and the percentage of ALK FISH-positive cells predict pulmonary adenocarcinoma prognosis: a prospective cohort study"],"prefix":"10.1186","volume":"19","author":[{"given":"Fenge","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Congcong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiannan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,16]]},"reference":[{"issue":"10","key":"2386_CR1","doi-asserted-by":"publisher","first-page":"e76999","DOI":"10.1371\/journal.pone.0076999","volume":"8","author":"H Kim","year":"2013","unstructured":"Kim H, Jang SJ, Chung DH, Yoo SB, Sun P, Jin Y, et al. A comprehensive comparative analysis of the histomorphological features of ALK-rearranged lung adenocarcinoma based on driver oncogene mutations: frequent expression of epithelial-mesenchymal transition markers than other genotype. PloS One. 2013;8(10):e76999. https:\/\/doi.org\/10.1371\/journal.pone.0076999.","journal-title":"PloS One"},{"issue":"1","key":"2386_CR2","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s12957-020-02041-0","volume":"18","author":"S Takashima","year":"2020","unstructured":"Takashima S, Imai K, Atari M, Matsuo T, Nakayama K, Sato Y, et al. Clinical benefits of adjuvant chemotherapy with carboplatin and gemcitabine in patients with non-small cell lung cancer: a single-center retrospective study. World J Surg Onc. 2020;18(1):263. https:\/\/doi.org\/10.1186\/s12957-020-02041-0.","journal-title":"World J Surg Onc."},{"issue":"1","key":"2386_CR3","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s12957-018-1515-2","volume":"16","author":"Y Chen","year":"2018","unstructured":"Chen Y, Wei S, Wang X, Zhu X, Han S. Progress in research on the role of circular RNAs in lung cancer. World J Surg Oncol. 2018;16(1):215. https:\/\/doi.org\/10.1186\/s12957-018-1515-2.","journal-title":"World J Surg Oncol."},{"issue":"8","key":"2386_CR4","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1097\/JTO.0b013e31821cfc73","volume":"6","author":"H Kim","year":"2011","unstructured":"Kim H, Yoo SB, Choe JY, Paik JH, Xu X, Nitta H, et al. Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression. J Thorac Oncol. 2011;6(8):1359\u201366. https:\/\/doi.org\/10.1097\/JTO.0b013e31821cfc73.","journal-title":"J Thorac Oncol"},{"issue":"9","key":"2386_CR5","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","volume":"10","author":"WD Travis","year":"2015","unstructured":"Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 World Health Organization Classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10(9):1243\u201360. https:\/\/doi.org\/10.1097\/JTO.0000000000000630.","journal-title":"J Thorac Oncol"},{"issue":"5151","key":"2386_CR6","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1126\/science.8122112","volume":"263","author":"SW Morris","year":"1994","unstructured":"Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science. 1994;263(5151):1281\u20134. https:\/\/doi.org\/10.1126\/science.8122112.","journal-title":"Science"},{"issue":"8","key":"2386_CR7","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1002\/cncr.27913","volume":"119","author":"AJ Weickhardt","year":"2013","unstructured":"Weickhardt AJ, Aisner DL, Franklin WA, Varella-Garcia M, Doebele RC, Camidge DR. Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer. Cancer. 2013;119(8):1467\u201377. https:\/\/doi.org\/10.1002\/cncr.27913.","journal-title":"Cancer"},{"issue":"3","key":"2386_CR8","doi-asserted-by":"publisher","first-page":"691","DOI":"10.4143\/crt.2017.280","volume":"50","author":"M Nishio","year":"2018","unstructured":"Nishio M, Kim DW, Wu YL, Nakagawa K, Solomon BJ, Shaw AT, et al. Crizotinib versus chemotherapy in Asian patients with ALK-positive advanced non-small cell lung cancer. Cancer Res Treat. Jul 2018;50(3):691\u2013700. https:\/\/doi.org\/10.4143\/crt.2017.280.","journal-title":"Cancer Res Treat"},{"issue":"1","key":"2386_CR9","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12957-016-0893-6","volume":"14","author":"P Incharoen","year":"2016","unstructured":"Incharoen P, Reungwetwattana T, Saowapa S, Kamprerasart K, Pangpunyakulchai D, Arsa L, et al. ALK-rearranged pulmonary adenocarcinoma in Thai Patients: from diagnosis to treatment efficacy. World J Surg. 2016;14(1):139. https:\/\/doi.org\/10.1186\/s12957-016-0893-6.","journal-title":"World J Surg."},{"key":"2386_CR10","doi-asserted-by":"publisher","unstructured":"Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. New Engl J Med. 2014;371(23):2167-21677. doi:https:\/\/doi.org\/10.1056\/NEJMoa1408440","DOI":"10.1056\/NEJMoa1408440"},{"issue":"1","key":"2386_CR11","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12957-020-01947-z","volume":"18","author":"X Zhang","year":"2020","unstructured":"Zhang X, Jiang Y, Yu H, Xia H, Wang X. A comprehensive study on the oncogenic mutation and molecular pathology in Chinese lung adenocarcinoma patients. World J Surg Oncol. 2020;18(1):172. https:\/\/doi.org\/10.1186\/s12957-020-01947-z.","journal-title":"World J Surg Oncol."},{"issue":"9","key":"2386_CR12","doi-asserted-by":"publisher","first-page":"4969","DOI":"10.21873\/anticanres.12815","volume":"38","author":"RL Millett","year":"2018","unstructured":"Millett RL, Elkon JM, Tabbara IA. Directed therapies in anaplastic lymphoma kinase-rearranged non-small cell lung cancer. Anticancer Res. 2018;38(9):4969\u201375. https:\/\/doi.org\/10.21873\/anticanres.12815.","journal-title":"Anticancer Res"},{"issue":"10","key":"2386_CR13","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1158\/1078-0432.CCR-14-2791","volume":"21","author":"R Katayama","year":"2015","unstructured":"Katayama R, Lovly CM, Shaw AT. Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine. Clin Cancer Res. 2015;21(10):2227\u201335. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2791.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2386_CR14","doi-asserted-by":"publisher","first-page":"80","DOI":"10.4103\/0019-509X.117007","volume":"50","author":"SS Desai","year":"2013","unstructured":"Desai SS, Shah AS, Prabhash K, Jambhekar NA. A year of anaplastic large cell kinase testing for lung carcinoma: pathological and technical perspectives. Indian J Cancer. 2013;50(2):80\u20136. https:\/\/doi.org\/10.4103\/0019-509X.117007.","journal-title":"Indian J Cancer."},{"issue":"2","key":"2386_CR15","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.lungcan.2012.03.004","volume":"77","author":"HS Park","year":"2012","unstructured":"Park HS, Lee JK, Kim DW, Kulig K, Kim TM, Lee SH, et al. Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients. Lung Cancer. 2012;77(2):288\u201392. https:\/\/doi.org\/10.1016\/j.lungcan.2012.03.004.","journal-title":"Lung Cancer."},{"issue":"1","key":"2386_CR16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/JTO.0b013e318274a83e","volume":"8","author":"CM Conklin","year":"2013","unstructured":"Conklin CM, Craddock KJ, Have C, Laskin J, Couture C, Ionescu DN. Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent. J Thorac Oncol. 2013;8(1):45\u201351. https:\/\/doi.org\/10.1097\/JTO.0b013e318274a83e.","journal-title":"J Thorac Oncol"},{"key":"2386_CR17","doi-asserted-by":"publisher","unstructured":"Hout DR, Schweitzer BL, Lawrence K, et al. Performance of a RT-PCR assay in comparison to FISH and immunohistochemistry for the detection of ALK in non-small cell lung cancer. Cancers. 2017;9(8). https:\/\/doi.org\/10.3390\/cancers9080099.","DOI":"10.3390\/cancers9080099"},{"issue":"3","key":"2386_CR18","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1097\/JTO.0b013e31820b82e8","volume":"6","author":"JH Paik","year":"2011","unstructured":"Paik JH, Choe G, Kim H, Choe JY, Lee HJ, Lee CT, et al. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization. J Thorac Oncol. 2011;6(3):466\u201372. https:\/\/doi.org\/10.1097\/JTO.0b013e31820b82e8.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"2386_CR19","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12957-015-0480-2","volume":"13","author":"K Kaseda","year":"2015","unstructured":"Kaseda K, Watanabe K, Asakura K, Kazama A. Surgical resection of lung adenocarcinoma after crizotinib treatment: report of a case. World J Surg Oncol. 2015;13(1):74. https:\/\/doi.org\/10.1186\/s12957-015-0480-2.","journal-title":"World J Surg Oncol"},{"issue":"10","key":"2386_CR20","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/j.jtho.2018.06.012","volume":"13","author":"YL Wu","year":"2018","unstructured":"Wu YL, Lu S, Lu Y, Zhou J, Shi YK, Sriuranpong V, et al. Results of PROFILE 1029, a phase III comparison of first-line crizotinib versus chemotherapy in East Asian patients with ALK-positive advanced non-small cell lung cancer. J Thorac Oncol. 2018;13(10):1539\u201348. https:\/\/doi.org\/10.1016\/j.jtho.2018.06.012.","journal-title":"J Thorac Oncol"},{"issue":"13","key":"2386_CR21","doi-asserted-by":"publisher","first-page":"21903","DOI":"10.18632\/oncotarget.15746","volume":"8","author":"M Duruisseaux","year":"2017","unstructured":"Duruisseaux M, Besse B, Cadranel J, et al. Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study. Oncotarget. 2017;8(13):21903\u201317. https:\/\/doi.org\/10.18632\/oncotarget.15746.","journal-title":"Oncotarget"},{"issue":"7","key":"2386_CR22","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/S1470-2045(17)30339-X","volume":"18","author":"AT Shaw","year":"2017","unstructured":"Shaw AT, Kim TM, Crino L, et al. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2017;18(7):874\u201386. https:\/\/doi.org\/10.1016\/S1470-2045(17)30339-X.","journal-title":"Lancet Oncol"},{"key":"2386_CR23","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2147\/LCTT.S209231","volume":"10","author":"S Gadgeel","year":"2019","unstructured":"Gadgeel S, Shaw AT, Barlesi F, et al. Time to response in patients with advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) receiving alectinib in the phase II NP28673 and NP28761 studies. Lung Cancer (Auckl). 2019;10:125\u201330. https:\/\/doi.org\/10.2147\/LCTT.S209231.","journal-title":"Lung Cancer (Auckl)"},{"key":"2386_CR24","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.lungcan.2019.08.010","volume":"136","author":"R Descourt","year":"2019","unstructured":"Descourt R, Perol M, Rousseau-Bussac G, Planchard D, Mennecier B, Wislez M, et al. Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study). Lung Cancer. 2019;136:109\u201314. https:\/\/doi.org\/10.1016\/j.lungcan.2019.08.010.","journal-title":"Lung Cancer."},{"issue":"13","key":"2386_CR25","first-page":"2495","volume":"36","author":"H Watanabe","year":"2009","unstructured":"Watanabe H, Okada M, Kaji Y, Satouchi M, Sato Y, Yamabe Y, et al. New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1). Gan to kagaku ryoho Cancer Chemother. 2009;36(13):2495\u2013501.","journal-title":"Gan to kagaku ryoho Cancer Chemother"},{"issue":"5","key":"2386_CR26","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1097\/JTO.0000000000000115","volume":"9","author":"MW Wynes","year":"2014","unstructured":"Wynes MW, Sholl LM, Dietel M, Schuuring E, Tsao MS, Yatabe Y, et al. An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators. J Thoracic Oncol. 2014;9(5):631\u20138. https:\/\/doi.org\/10.1097\/JTO.0000000000000115.","journal-title":"J Thoracic Oncol."},{"key":"2386_CR27","doi-asserted-by":"publisher","unstructured":"Tang Z, Wang L, Tang G, Medeiros LJ. Fluorescence in Situ Hybridization (FISH) for Detecting Anaplastic Lymphoma Kinase (ALK) Rearrangement in Lung Cancer: Clinically Relevant Technical Aspects. Int J Mole Sci. 2019;20(16). https:\/\/doi.org\/10.3390\/ijms20163939.","DOI":"10.3390\/ijms20163939"},{"issue":"11","key":"2386_CR28","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1002\/cncy.21314","volume":"121","author":"EF Rodriguez","year":"2013","unstructured":"Rodriguez EF, Monaco SE, Dacic S. Cytologic subtyping of lung adenocarcinoma by using the proposed International Association for the Study of Lung Cancer\/American Thoracic Society\/European Respiratory Society (IASLC\/ATS\/ERS) adenocarcinoma classification. Cancer Cytopathol. 2013;121(11):629\u201337. https:\/\/doi.org\/10.1002\/cncy.21314.","journal-title":"Cancer Cytopathol"},{"issue":"9","key":"2386_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3941\/jrcr.v10i9.2590","volume":"10","author":"G Abrego","year":"2016","unstructured":"Abrego G, Garcia J, Gilbert B, Forseen S, Toscano M. ALK positive Anaplastic Large Cell Lymphoma of the Thoracic Spine. J Radiol Case Rep. 2016;10(9):1\u201312. https:\/\/doi.org\/10.3941\/jrcr.v10i9.2590.","journal-title":"J Radiol Case Rep"},{"issue":"6","key":"2386_CR30","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1080\/17843286.2017.1312057","volume":"72","author":"S Al-Ahmad","year":"2017","unstructured":"Al-Ahmad S, Maertens V, Libeer C, et al. The masquerading presentation of a systemic anaplastic large cell lymphoma, ALK positive: a case report and review of the literature. Acta Clin Belg. 2017;72(6):454\u201360. https:\/\/doi.org\/10.1080\/17843286.2017.1312057.","journal-title":"Acta Clin Belg"},{"key":"2386_CR31","doi-asserted-by":"publisher","unstructured":"Rico-Jimenez J, Lee JH, Alex A, et al. Non-invasive monitoring of pharmacodynamics during the skin wound healing process using multimodal optical microscopy. BMJ Open Diabetes Res Care. 2020;8(1). https:\/\/doi.org\/10.1136\/bmjdrc-2019-000974.","DOI":"10.1136\/bmjdrc-2019-000974"},{"issue":"12","key":"2386_CR32","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1002\/ijc.31275","volume":"142","author":"P Christopoulos","year":"2018","unstructured":"Christopoulos P, Endris V, Bozorgmehr F, et al. EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK(+) non-small cell lung cancer. Int J Cancer. 2018;142(12):2589\u201398. https:\/\/doi.org\/10.1002\/ijc.31275.","journal-title":"Int J Cancer"},{"issue":"11","key":"2386_CR33","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1634\/theoncologist.2012-0311","volume":"17","author":"SH Ou","year":"2012","unstructured":"Ou SH, Bartlett CH, Mino-Kenudson M, Cui J, Iafrate AJ. Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology. The oncologist. 2012;17(11):1351\u201375. https:\/\/doi.org\/10.1634\/theoncologist.2012-0311.","journal-title":"The oncologist."},{"issue":"5","key":"2386_CR34","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/nrclinonc.2012.43","volume":"9","author":"DR Camidge","year":"2012","unstructured":"Camidge DR, Doebele RC. Treating ALK-positive lung cancer\u2014early successes and future challenges. Nat Rev Clin Oncol. 2012;9(5):268\u201377. https:\/\/doi.org\/10.1038\/nrclinonc.2012.43.","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"2386_CR35","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1634\/theoncologist.2014-0241","volume":"19","author":"D Kazandjian","year":"2014","unstructured":"Kazandjian D, Blumenthal GM, Chen HY, He K, Patel M, Justice R, et al. FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements. The oncologist. 2014;19(10):e5\u201311. https:\/\/doi.org\/10.1634\/theoncologist.2014-0241.","journal-title":"The oncologist."},{"issue":"7","key":"2386_CR36","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.3978\/j.issn.2072-1439.2015.06.04","volume":"7","author":"YY Lei","year":"2015","unstructured":"Lei YY, Yang JJ, Zhong WZ, Chen HJ, Yan HH, Han JF, et al. Clinical efficacy of crizotinib in Chinese patients with ALK-positive non-small-cell lung cancer with brain metastases. J Thorac Dis. 2015;7(7):1181\u20138. https:\/\/doi.org\/10.3978\/j.issn.2072-1439.2015.06.04.","journal-title":"J Thorac Dis"},{"issue":"10","key":"2386_CR37","doi-asserted-by":"publisher","first-page":"e0205827","DOI":"10.1371\/journal.pone.0205827","volume":"13","author":"S Lu","year":"2018","unstructured":"Lu S, Yu Y, Fu S, Ren H. Cost-effectiveness of ALK testing and first-line crizotinib therapy for non-small-cell lung cancer in China. PloS One. 2018;13(10):e0205827. https:\/\/doi.org\/10.1371\/journal.pone.0205827.","journal-title":"PloS One."},{"issue":"3","key":"2386_CR38","doi-asserted-by":"publisher","first-page":"257","DOI":"10.4103\/0970-2113.180801","volume":"33","author":"VN Maturu","year":"2016","unstructured":"Maturu VN, Singh N, Bal A, Gupta N, Das A, Behera D. Relationship of epidermal growth factor receptor activating mutations with histologic subtyping according to International Association for the Study of Lung Cancer\/American Thoracic Society\/European Respiratory Society 2011 adenocarcinoma classification and their impact on overall survival. Lung India. 2016;33(3):257\u201366. https:\/\/doi.org\/10.4103\/0970-2113.180801.","journal-title":"Lung India"},{"issue":"2","key":"2386_CR39","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1080\/08998280.2018.1559672","volume":"32","author":"DS Grosser","year":"2019","unstructured":"Grosser DS, Zhang H. Histomorphologic features of lung adenocarcinomas exhibiting ALK gene rearrangement. Proceedings. 2019;32(2):206\u20138. https:\/\/doi.org\/10.1080\/08998280.2018.1559672.","journal-title":"Proceedings."},{"issue":"11","key":"2386_CR40","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1002\/dc.23800","volume":"45","author":"K Miyata","year":"2017","unstructured":"Miyata K, Morita S, Dejima H, Seki N, Matsutani N, Mieno M, et al. Cytological markers for predicting ALK-positive pulmonary adenocarcinoma. Diagn Cytopathol. 2017;45(11):963\u201370. https:\/\/doi.org\/10.1002\/dc.23800.","journal-title":"Diagn Cytopathol"},{"issue":"4","key":"2386_CR41","doi-asserted-by":"publisher","first-page":"310","DOI":"10.4132\/jptm.2015.05.13","volume":"49","author":"IH Choi","year":"2015","unstructured":"Choi IH, Kim DW, Ha SY, Choi YL, Lee HJ, Han J. Analysis of histologic features suspecting anaplastic lymphoma kinase (ALK)-expressing pulmonary adenocarcinoma. J Pathol Transl Med. 2015;49(4):310\u20137. https:\/\/doi.org\/10.4132\/jptm.2015.05.13.","journal-title":"J Pathol Transl Med"},{"issue":"12","key":"2386_CR42","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.1002\/1097-0142(20000615)88","volume":"88","author":"P Kleihues","year":"2000","unstructured":"Kleihues P, Sobin LH. World Health Organization classification of tumors. Cancer. 2000;88(12):2887. https:\/\/doi.org\/10.1002\/1097-0142(20000615)88 12<2887::aid-cncr32>3.0.co;2-f.","journal-title":"Cancer"},{"issue":"12","key":"2386_CR43","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1097\/PAS.0000000000000280","volume":"38","author":"JM Boland","year":"2014","unstructured":"Boland JM, Wampfler JA, Jang JS, Wang X, Erickson-Johnson MR, Oliveira AM, et al. Pulmonary adenocarcinoma with signet ring cell features: a comprehensive study from 3 distinct patient cohorts. Am J Surg Pathol. 2014;38(12):1681\u20138. https:\/\/doi.org\/10.1097\/PAS.0000000000000280.","journal-title":"Am J Surg Pathol"},{"issue":"11","key":"2386_CR44","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1038\/modpathol.2012.109","volume":"25","author":"M Nishino","year":"2012","unstructured":"Nishino M, Klepeis VE, Yeap BY, Bergethon K, Morales-Oyarvide V, Dias-Santagata D, et al. Histologic and cytomorphologic features of ALK-rearranged lung adenocarcinomas. Modern Pathol. 2012;25(11):1462\u201372. https:\/\/doi.org\/10.1038\/modpathol.2012.109.","journal-title":"Modern Pathol"},{"issue":"8","key":"2386_CR45","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1097\/PAS.0b013e3182233e06","volume":"35","author":"A Yoshida","year":"2011","unstructured":"Yoshida A, Tsuta K, Nakamura H, Kohno T, Takahashi F, Asamura H, et al. Comprehensive histologic analysis of ALK-rearranged lung carcinomas. Am J Surg Pathol. 2011;35(8):1226\u201334. https:\/\/doi.org\/10.1097\/PAS.0b013e3182233e06.","journal-title":"Am J Surg Pathol"},{"issue":"26","key":"2386_CR46","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.1200\/JCO.2009.22.6993","volume":"27","author":"AT Shaw","year":"2009","unstructured":"Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009;27(26):4247\u201353. https:\/\/doi.org\/10.1200\/JCO.2009.22.6993.","journal-title":"J Clin Oncol"},{"issue":"16","key":"2386_CR47","doi-asserted-by":"publisher","first-page":"5216","DOI":"10.1158\/1078-0432.CCR-09-0802","volume":"15","author":"SJ Rodig","year":"2009","unstructured":"Rodig SJ, Mino-Kenudson M, Dacic S, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res. 2009;15(16):5216\u201323. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-0802.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2386_CR48","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/sj.onc.1200849","volume":"14","author":"T Iwahara","year":"1997","unstructured":"Iwahara T, Fujimoto J, Wen D, et al. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene. 1997;14(4):439\u201349. https:\/\/doi.org\/10.1038\/sj.onc.1200849.","journal-title":"Oncogene"},{"issue":"8","key":"2386_CR49","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1097\/PAI.0000000000000675","volume":"27","author":"L Lambros","year":"2019","unstructured":"Lambros L, Ginestet F, Quintin-Roue I, Le Flahec G, Uguen A. Combining ALK fluorescent in situ hybridization and immunohistochemistry to analyze multiple non-small cell lung carcinoma samples per patient reveals intermethod and intersample-discrepant results. Applied Immunohistochem Mole Morphol. 2019;27(8):565\u201371. https:\/\/doi.org\/10.1097\/PAI.0000000000000675.","journal-title":"Applied Immunohistochem Mole Morphol"},{"key":"2386_CR50","doi-asserted-by":"publisher","unstructured":"Bian C, Li Z, Xu Y, et al. Clinical outcome and expression of mutant P53, P16, and Smad4 in lung adenocarcinoma: a prospective study. World J Surg Onc. 2015;13(128). https:\/\/doi.org\/10.1186\/s12957-015-0502-0.","DOI":"10.1186\/s12957-015-0502-0"},{"issue":"9","key":"2386_CR51","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1093\/annonc\/mdy242","volume":"29","author":"JC Soria","year":"2018","unstructured":"Soria JC, Ho SN, Varella-Garcia M, et al. Correlation of extent of ALK FISH positivity and crizotinib efficacy in three prospective studies of ALK-positive patients with non-small-cell lung cancer. Ann Oncol. 2018;29(9):1964\u201371. https:\/\/doi.org\/10.1093\/annonc\/mdy242.","journal-title":"Ann Oncol"},{"issue":"2","key":"2386_CR52","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jmoldx.2017.11.004","volume":"20","author":"NI Lindeman","year":"2018","unstructured":"Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. The Journal of molecular diagnostics : JMD. 2018;20(2):129\u201359. https:\/\/doi.org\/10.1016\/j.jmoldx.2017.11.004.","journal-title":"The Journal of molecular diagnostics : JMD."}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-021-02386-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-021-02386-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-021-02386-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T16:04:37Z","timestamp":1631808277000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-021-02386-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,16]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2386"],"URL":"https:\/\/doi.org\/10.1186\/s12957-021-02386-0","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,16]]},"assertion":[{"value":"27 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and approved by the ethics committee of Yuhuangding Hospital Affliated to Qingdao University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"278"}}